Tag: risk

SINGAPORE, July 19, 2025 (GLOBE NEWSWIRE) -- As Bitcoin surpasses $120,000 and Ethereum hovers near $3,600, the long-anticipated crypto bull market is officially here. In response, BexBack, the rapidly rising crypto futures exchange, is doubling down on its commitment to empower both new and seasoned traders. The platform is now offering a 100% deposit bonus, a $50 welcome bonus, up to 100x leverage, and most importantly — no KYC requirements.

LONDON, UK, July 19, 2025 (GLOBE NEWSWIRE) -- As global regulators and institutional players intensify their scrutiny of the cryptocurrency mining industry, Ja Mining has completed an independent third-party security audit to evaluate and reinforce the platform’s operational integrity. This development comes at a critical moment, with growing industry-wide demands for transparency, cybersecurity, and risk mitigation across decentralized digital asset infrastructures.

Retail investors gain first-of-its-kind on‑chain access to early‑stage private equity in nuclear micro‑reactors

BROOKLYN, New York , July 19, 2025 (GLOBE NEWSWIRE) -- LTESocks.io, a leading provider of high-performance mobile proxy solutions, today announced its ambitious 2025 technology roadmap designed to build the next generation of network infrastructure for its global client base. The multi-phase initiative focuses on fundamentally enhancing speed, reliability, and scalability by integrating cutting-edge protocols and expanding its state-of-the-art 5G network.

NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares (“ADSs”) of Reckitt Benckiser Group PLC (OTC: RBGLY) between January 13, 2021 and July 28, 2024, both dates inclusive (the “Class Period”), of the important August 4, 2025 lead plaintiff deadline.

Phoenix platform matches users with genetically similar people to predict which interventions actually work.

SAN CARLOS, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on July 17, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 138,190 shares of Iovance’s common stock to 20 new, non-executive employees.